Abstract
Very few randomised clinical trials have investigated the available treatments for primary immune thrombocytopenia.1,2 Rituximab was introduced as a treatment for primary immune thrombocytopenia in the early 2000s and was quickly adopted as an effective second-line treatment, but its use is mainly based on results from uncontrolled observational studies. The results from these investigations—including 300 adult patients in 19 studies—were systematically reviewed by Arnold and colleagues in 2007.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
